Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. - Wikidata - awgldk - TriplyDB

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

http://www.wikidata.org/entity/Q34842494

about

Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.Tamoxifen and CYP2D6: a contradiction of data.Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.Effects of CYP induction by rifampicin on tamoxifen exposure.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Individualization of tamoxifen treatment for breast carcinoma.Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods.Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance.Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Clinical and biomarker predictors of side effects from tamoxifen Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.Cancer pharmacogenomics Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.

P2860

Q28485336-4477040D-2146-4C8A-8BAA-EDF65A6A9DFC Q30662550-23CA1842-1E54-4FED-BF60-13FD5E51FCE4 Q33756964-0C66760C-1E3F-4F5F-AF74-85EC73454F8F Q34244463-9B221427-7846-40E7-AC93-81D215E1B656 Q34269380-CF0D3281-17F2-43A4-8DBE-326B8CD4813E Q34278391-D2E797ED-603A-496C-927D-09326CE79D77 Q34307589-AD94DFB6-DBA8-4237-9658-4C66926A8885 Q34387066-83CE35C1-9CE7-4B04-A3DC-CF49AC680548 Q34571065-700AA6ED-1180-4A85-9B76-45845B139B05 Q34736986-F0343163-3E12-4255-B176-9987A22C2A87 Q34768999-BE514366-5118-48FC-90B3-869F89CF85FF Q35020403-492FFEC9-E4B0-496D-A0F5-9749564C8B11 Q35076890-27764355-D96D-4BB6-AD99-C0ACBD6E9024 Q35111746-7AADE1B9-79AD-4A12-AAC6-BF991AF39403 Q35129546-7C544585-9417-467B-A95F-8B1E349288C1 Q35168556-E7DAFAEB-0D0D-4C38-8E34-A7A67AF06718 Q35206306-C4494C40-C481-4EA4-A283-AABA1C9477EB Q35510803-2658D64D-2900-4DAB-B236-32D97F3BD1F1 Q35732619-A7E8166D-2919-44B6-985E-940239AF79B8 Q35747766-D6C70883-C444-411C-8F91-30FA4D83BD5C Q35842986-6F7EF74A-9684-425D-8422-AAF6B388B32B Q35884159-DD856780-CD5B-4C95-A8EE-2352BE515A51 Q35911174-E43CB394-1B5F-4079-A680-8085CB5E2EE6 Q35915042-1FBE59EB-47DB-4587-ABCE-52B1DE1D63B2 Q35975826-CC21CB64-0EB6-498A-844B-AF34BC0CD15D Q35996187-09653138-A4B4-49C6-A0C3-D978583D9E31 Q36015010-B1DDF144-2AA7-43C6-A98B-8E03651789B7 Q36047387-FF5BA973-3988-45F3-BDCB-D2719CAD64CB Q36107130-2A5C1763-3C23-434F-BCA0-AB561D8E19CF Q36109257-99B9992F-5E01-4D5E-9BB0-D6F4E8549D32 Q36125233-77D998E2-B1D8-4AD6-A029-67AB52331641 Q36243663-0230A517-E2A5-438A-BBC2-69B71428991D Q36441521-8E6D6EB0-D0E9-4243-B1DA-66F3A19246BD Q36535678-C604A733-2F17-4249-BF57-A1FC16BBE5D6 Q36545056-C45BC0DE-0EBD-4962-A054-B77CE34F2C86 Q36550926-C9DD291D-F431-430E-A90E-FB27352B0601 Q36586900-67DE646A-6658-4A1F-84BD-9885802066CF Q36772047-028C7ABD-00EB-42EE-B8CF-E6274E4C30AA Q36822291-A823E6B6-8A17-40A9-9576-2CF95775EB62 Q37059751-635D4CF6-DFA2-48CA-9921-33DA5C5DF383

P2860

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

http://www.wikidata.org/entity/Q34842494

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@ast

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@en

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@nl

type

label

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@ast

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@en

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@nl

prefLabel

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@ast

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@en

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

@nl

P1433

Q34842494-1AFBBFB6-179E-453A-BEC2-12B51E7B8311

P1476

Q34842494-5CE4ABDA-C302-4D53-A36B-A5C500C8D11B

P2093

Q34842494-2C3491EC-F2A6-480E-B1FC-EEB8CF53D82C

Q34842494-452925A2-1F05-4A96-AEF1-D900A3890B13

Q34842494-9E1B005A-2BEA-4846-B69D-83A7F3862659

Q34842494-C79CB1DE-44C1-4A28-B5C1-F9A9A575EEFC

Q34842494-CCC7ECC5-8E04-448B-BB2E-26FEE680FA40

Q34842494-CF011D6D-FA08-4E91-9C07-66435B800B72

Q34842494-D2BC6536-DBF6-42A4-8380-F9940DACE3FE

Q34842494-D6A72520-5E5E-4527-AE6F-E429FF09C06F

Q34842494-EF1DFAA8-AA56-4232-8D2B-CD6A391A2351

Q34842494-F1C7AFE0-5D54-42D8-A6B1-AD49C314F703

P2860

Q34842494-0E835456-E12A-4456-A809-8AB0338D6E2F

Q34842494-1111192F-7659-4854-8A9C-1642AAB16B2F

Q34842494-2431BB49-E2D2-4A22-A8F4-C79F2C2FF4A6

Q34842494-5409541C-294F-435E-9E67-0ACED96D2A2E

Q34842494-5BDE2533-6731-44C0-837B-50B39BB2ACD5

Q34842494-5F0FEC23-A5EE-4CFD-AA79-F529FA8B4F57

Q34842494-64277DEA-8F1B-4575-978F-9EA0CEA48956

Q34842494-68997534-E87D-4C22-B119-7FD00A64B847

Q34842494-974900CF-DA88-4181-BB8F-64A1CE8C1FBB

Q34842494-A02F7401-8CE1-4B62-835D-3A86EB5A8919

P304

Q34842494-4152C7C9-4803-4393-9FAD-7D3E3BE66D37

P31

Q34842494-26668162-D791-4DCC-92B1-1CE95391424A

P356

Q34842494-1B1799B5-048F-40EE-9BEF-358467B4D724

P407

Q34842494-E71D88EA-559E-4C4D-B37A-4BABB83D3F76

P433

Q34842494-B9E906F3-6D6A-4222-A77C-FB86BA452B82

P478

Q34842494-0A95CBB0-ACEC-4CD5-99B2-91BB60651E40

P50

Q34842494-62891438-F557-4F79-98AB-FC279332BE70

P577

Q34842494-4A27EB0A-BB73-471A-AA74-CF81F58C381B

P5875

Q34842494-560B43B0-611C-4BB6-A160-C327C3A95739

P698

Q34842494-6751CBC3-5899-42A8-B45C-0C713182224F

P932

Q34842494-97563223-D83B-4CAA-8814-EAFDF45E5A05

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes

@en

P2093

A H B Wu

http://www.w3.org/2001/XMLSchema#string

B A Parker

http://www.w3.org/2001/XMLSchema#string

D M Nikoloff

http://www.w3.org/2001/XMLSchema#string

G Hillman

http://www.w3.org/2001/XMLSchema#string

H J Lawrence

http://www.w3.org/2001/XMLSchema#string

J P Pierce

http://www.w3.org/2001/XMLSchema#string

L Madlensky

http://www.w3.org/2001/XMLSchema#string

L Natarajan

http://www.w3.org/2001/XMLSchema#string

M Pu

http://www.w3.org/2001/XMLSchema#string

M R Fontecha

http://www.w3.org/2001/XMLSchema#string

P2860

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Genotype-guided tamoxifen therapy: time to pause for reflection?

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Selective serotonin-reuptake inhibitors for the treatment of hot flashes.

Tamoxifen, hot flashes and recurrence in breast cancer.

CYP2D6 genotyping and the pharmacogenetics of tamoxifen.

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Time-varying effects of prognostic factors associated with disease-free survival in breast cancer.

P304

718-725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2011.32

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P50

Joanne E Mortimer

P577

2011-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50832030

http://www.w3.org/2001/XMLSchema#string

P698

21430657

http://www.w3.org/2001/XMLSchema#string

P932

3081375

http://www.w3.org/2001/XMLSchema#string